Contrast solution producer Guerbet is seeking to reduce variability in radiation dose management with help from Imalogix’s AI-based process and workflow solutions.

The Imalogix Platform equips providers with a series of cloud-based and machine learning capabilities to better manage the process, quality and safety of diagnostic imaging and interventional practices, and to adapt to changing regulatory standards for radiation dose management to provide quality, safety and efficiency to patient care.

“The Imalogix Platform brings a new level of insights to healthcare delivery that will allow Guerbet customers to accelerate meaningful change to deliver consistent high-quality, safe and effective care for every patient,” John Heil, CEO of Imalogix, told HCB News. “By combining the strength of the Imalogix cloud-based AI workflow platform with Guerbet's leadership in diagnostic and interventional imaging, customers have access to a complete solution to better understand and manage processes, quality and safety for patients.”

The self-learning neural network continuously drives improvement by creating benchmarks in real-time best practices from data derived from across a network of providers. Its insights focus on practices around procedure length, utilization and workflow for patient flow optimization, with the latest version of the platform introduced last month.

In exchange, Guerbet will supply the Imalogix team with its leadership and experience to further build on the company’s expertise in diagnostic and interventional imaging.

The collaboration falls in line with Guerbet’s contributions to the Association for Medical Imaging Management (AHRA) "Defining Our Future" campaign, an initiative supporting the education, development, and empowerment of new and future medical imaging professionals. The company made its latest contribution of $50,000 in July.

It also announced another partnership that same month with IBM Watson for the development of the Watson Imaging Care Advisor for Liver, an AI-based platform designed to support liver diagnostics in CT and MR imaging.

Heil says that the partnership between Imalogix and Guerbet demonstrates the increasing focus on personalized optimization for dose within the healthcare community and the need to approach the dose conversation from a variety of angles.

“We are going far beyond retrospective reporting of radiation dose and are focused on helping providers understand improvements that can be made down to the scanner, protocol or operator level to proactively manage risk and continuously improve quality and efficiency,” he said. “Ultimately, we will be able to predict the optimal amount of dose per exam to support the right image quality to enable a definitive diagnosis for every single exam. This will transform how radiation dose is currently viewed in the industry.”

Health IT Homepage